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Abstract
Background: Health-related quality of life (HRQoL) before treatment may predict survival of patients with non-
small-cell lung cancer (NSCLC). We investigated the predictive role of HRQoL after the initial treatments, on the sur-
vival of these patients.
Methods: A prospective multi-center study conducted in northeastern France. The SF-36 and European
Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (QLQ C-30) were mailed
to patients 3 months after the end of the diagnostic process. High scores for functioning dimensions on both
questionnaires indicated better QoL, and low scores for symptom dimensions on the QLQ C-30 indicated few
symptoms. Cox regression modeling was used to identify predictive factors of survival.
Results: In total, 230 (63.5%) patients responded to the SF-36 and QLQ C-30. Before completing the questionnaires,
almost 60% of patients had undergone some chemotherapy, about 10% underwent radio/chemotherapy or both and
more than 30% underwent surgery or surgery plus chemo/radiotherapy.
On SF-36, the highest mean score was for social functioning dimension (55.5 ± 28), and the lowest was for the physical
role dimension (17.9 ± 32.2).
On QLQ C-30, for the functioning dimensions, the highest mean score was for cognitive functioning (74.6 ± 25.9) and
the lowest was for role functioning (47.2 ± 34.1). For symptom dimensions, the lowest score was for diarrhoea
(11.5 ± 24.2) and the highest was for fatigue (59.7 ± 27.7).
On multivariate analysis, high bodily pain, social functioning and general health scores (SF-36) were associated
with a lower risk of death (hazard ratio 0.580; 95% confidence interval [0.400–0.840], p = 0.004; HR 0.652 [0.455–0.935],
p < 0.02; HR 0.625 [0.437–0.895] respectively). Better general QoL on QLQ C-30 was related to lower risk of death
(HR 0.689 [0.501–0.946], p = 0.02).
Conclusion: Adding to previous knowledge about factors that may influence patients QoL, this study shows a
persisting relationship between better perceived health in HRQoL after the initial treatment of NSCLC and better
survival.
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Introduction
Lung cancer is considered the greatest contributor to
death from cancer. It accounts for 1,180,000 deaths per
year worldwide [1] and in France 26,624 deaths in 2005.
In France, its incidence and mortality rates have de-
creased by 0.5% and 1.7%, respectively, since 1980 for
men, but have increased for women [2]. Non-small-cell
lung cancer (NSCLC) is accounted for 80% of these new
cases [3,4] and survival time for all stages of NSCLC
(I, II, III-IV) is low with a median of 43.3 months [4].
Therefore, all prognostic factors must be identified in
this group of patients to provide insights into the dis-
ease process and the therapeutic response.
Patient-reported outcomes, including health-related qual-
ity of life (HRQoL), symptoms, and functional status, are
well established and useful in oncology for describing the
clinical disease course, helping to select optimal treatment,
or comparing populations of cancer patients with those
having other diseases and with the general population
[5-9]. In general, HRQoL covers subjective perceptions of
the positive and negative aspects of patient symptoms, in-
cluding physical, emotional, social and cognitive functions,
and importantly, disease symptoms and side effects of treat-
ments [10]. Clinicians are increasingly considering HRQoL
as critical to cancer patient care [11,12].
Different instruments have been developed and vali-
dated [13,14], and recently, researchers have begun to
study the relation between HRQoL and patient’s sur-
vival. Often, patient HRQoL is measured after cancer
diagnosis and before any treatment, and studies have
shown different results. For example, measuring by the
European Organization for Research and Treatment of
Cancer (EORTC), Quality of Life Questionnaire Core-30
(QLQ C30), global HRQoL assessed before treatment,
was found to be a strong predictor of survival in patients
with NSCLC and lymph node abnormalities [15]. With
this same instrument, another study showed that patient
self-reported pain and dysphagia predicted overall survival
in advanced NSCLC, independently of socio-demographic
or clinical characteristics [16]. Fielding et al. used the
Functional Assessment of Cancer Therapy-General instru-
ment to measure patients with liver and lung cancer
HRQoL in China and found that only physical well-being
subscale predicted lung cancer survival [17]. However,
Hernsdon et al. showed that after adjusting for clinical
factors, the pain perceived by patients predicted survival,
whereas overall HRQoL of the QLQ C-30 did not [18].
These heterogeneous results indicate that more research
is needed to better understand the role of patient’s QoL
on survival. In particular, the diagnostic process ending
with delivery of the diagnosis and the treatment strategy
that can be sources of psychological challenge [19,20], and
the early period of treatment that may add potential dis-
tress. Measuring HRQoL within months after the end of
the diagnosis process reflects both the effect of the dis-
ease evolution and of the treatments during this period. A
3-month time frame period after the diagnosis process
gives enough time to patients to undertake and receive
some benefits from their treatments and at the same time
to avoid a selection bias due to loosing too many patients.
Whether the treatment received has levelled off the pre-
dictive value of HRQoL on survival remains unknown.
We aimed to investigate whether HRQoL after the initial
treatment still plays a role in predicting survival in pa-
tients with NSCLC. We used the Medical Outcomes
Study Short Form 36 (SF-36) and the QLQ C-30 to evalu-
ate HRQoL. The SF-36 has been useful in surveys of
general and specific populations comparing the relative
burden of diseases and differentiating the health benefits
produced by a wide range of treatments [14,21]. The QLQ
C-30 allowed identifying health problems related to cancer
and its treatments, such as pain, diarrhoea, nausea and
vomiting, as well as appetite loss [13,15].
Methods
Design
A prospective multi-center study was conducted in
northeastern France (Alsace, Lorraine, Franche-Comté,
Bourgogne, and Champagne-Ardenne) as part of re-
search reported elsewhere [22-24]. The study involved 18
health-administrative districts covering 8.22 million
people. Fifty physicians in 18 principal hospitals, public or
private, in each region participated and reported the cases
of lung cancer in their hospital occurring from July 2002
to June 2006. The study was approved by the Institu-
tional Review Board (Commission National d’Informa-
tique et Liberté [CNIL]).
Samples
The inclusion criteria were patients with NSCLC; were
at least 18 years old; underwent the pre-therapeutic
process within the participating regions; began their
treatment < 10 weeks before inclusion; were able to read
and understand French, and to complete self-reported
questionnaires.
Data collection
For each reported case, a research assistant in each re-
gion verified the patient’s medical record and noted the
patient’s sociodemographic characteristics (age, sex, and
level of education), stage of cancer, health-examinations
that patient undertook during the diagnostic process,
and all treatment (radiotherapy, chemotherapy or sur-
gery) undertook after the end of the diagnosis process
until the HRQoL measure.
Information on patients’ vital status at the end of
follow-up was obtained by accessing the Repertoire
National d’Identification des Personnes Physiques, a
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register of death certificates with documented medical
cause (CNIL authorization n° 908413, November 2008).
HRQoL measure
The date when the physician decided to stop diagnostic
investigations or begin treatment was considered as the
end of the diagnostic process. HRQoL was assessed by
the generic (SF-36) and cancer-specific (QLQ C-30) self-
administered questionnaires mailed 10 (+2) weeks after
this date.
The SF-36, a multipurpose health survey with 36 ques-
tions, measures HRQoL status during the previous
4 weeks. Scores range from 0 to 100, with high scores
reflecting better QoL. The survey yields scores for 8
scales or dimensions of functional health and well-
being: physical functioning, physical role, bodily pain,
general health, vitality, social functioning, emotional
role and mental health. The questionnaire allows for
a psychometrically based physical component summary
(PCS) that measures the absence of physical limitations,
disability or decrease in well-being and energy level and a
mental component summary (MCS) that measures the
absence of psychological distress and limitations in
usual social or role activities because of emotional prob-
lems during the last 8 days.
The cancer-specific instrument was the QLQ C-30.
The survey contains 30 questions addressing various
aspects of HRQoL. Following EORTC guidelines, sub-
scale scores were converted to a 0–100 scale. High scores
represent a better level of functioning for the functional
and global health status and more severe symptoms for
the symptom scales. The reliability and validity of this
questionnaire have been confirmed in a number of
international studies for patients with different cancers,
including lung cancer [13,15]. It measured the HRQoL of
patients during the week before the measure.
The generic and cancer-specific questionnaires were
complementary.
Statistical analysis
The analysis was done on data of patients who returned
back HRQoL measures (SF-36 and QLQ-C30) and on
which the scores could be calculated. Questionnaires
with missing data were handled according to imputation
method recommended by the developers.
Descriptive analysis
HRQoL scores were described with means ± SD, median
and quartile 1 (Q1) and Q3. To test the association be-
tween variables, the chi-square or Fisher exact test
was used for qualitative variables and Student t test
or Mann–Whitney test for quantitative variables.
Survival analysis
Using survival as the outcome, the time to event (death)
was determined from the date when patients completed
the HRQoL questionnaire to the date of death (due to
any cause = overall survival). Patients who were alive on
May 1, 2010 or were lost to follow-up were censored.
Survival curves were estimated by the Kaplan-Meier
method and compared by the log rank test. Bivariate
analyses involved use of the Cox proportional hazards
model to identify HRQoL dimensions and patient charac-
teristics related to survival: age (as a continuous variable),
sex, cancer stage, and treatment. The proportionality as-
sumption was checked for each of the variables under
study with scaled Schoenfeld residuals and by the propor-
tionality test [25-27]. According to Van Steen et al. [28],
global HRQoL score is highly correlated with 7 of 11
scores of the QLQ C-30, and the authors suggested ex-
cluding this variable from the final model when analyzing
prognostic factors. In addition, both SF-36 summaries are
highly correlated with 4 of the scale’s 10 dimensions [14].
The PCS is related to physical functioning, role physical,
bodily pain and general health dimensions and the MCS to
vitality, social functioning, role emotional and mental
health [29]. Accordingly, we built several models on multi-
variate analysis using the Cox model. Survival was used as
independent variable, and certain dimensions on the SF-36
and QLQ C-30 that were statistically significant on bivari-
ate analysis were used as candidate predictors as explained
below. We also tested first-order interactions between age,
sex, stage of cancer and treatment before QoL measure.
Significant interactions were included in the models.
Models with SF-36 scores
Model 1: All HRQoL dimension scores except global
health, PCS, and MCS scores.
Model 2: General health score only.
Models with QLQ C-30 scores
Model 4: All HRQoL dimension scores except global
HRQoL score.
Model 5: Global HRQoL score only.
Each model was adjusted on patients’ age and sex, can-
cer stage and treatments before HRQoL measurement.
Treatment was classified into 3 classes: 1) radiotherapy
and chemotherapy, 2) surgery alone or surgery and (radio-
therapy or chemotherapy), and 3) chemotherapy only.
The multivariate analysis involved all variables that
were significantly related to survival on bivariate analysis
at p < 0.1. A p < 0.05 was considered statistically significant
for all analyses. Analyses involved use of SAS 9.3 (SAS
Inst., Cary, NC).
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Results
Patient characteristics
Among 429 NSCLC patients identified for the study,
67 patients died before we distributed the question-
naire 3 months after the diagnostic process. Of 362 poten-
tial participants, 230 (63.5%) returned back and completed
the SF-36 and the QLQ C-30 (Figure 1). Patients who
died before 3 months were older (mean 64.2 ± 1.3 years;
p = 0.02) and more often had stage 4 NSCLC (p = 0.002)
than patients who were still alive and could participate in
the study. Before completing the questionnaires, most
participating patients had received some treatments:
almost 60% received chemotherapy only during 82.5 ±
61.3 days, about 11% had some chemo and radiother-
apy; and more than 30% underwent surgical treatment
and chemo/radiotherapy (Table 1). The mean delay be-
tween the beginning of treatment and when patients
completed the questionnaires was 71.9 ± 34.2 days.
No difference between responders (n = 230) vs non-
responders (n = 132) was observed for: age, p = 0.6; sex,
p = 0.9; education level, p = 0.5; treatments, p = 0.08, stage,
p = 0.5. Neither for the median survival of both groups
(15.5 months [CI 95% = 10 – 30] for patients non-
responders the questionnaires, and 18.5 months [14 – 27]
for responders.
At the end of the follow-up (up to 8 years; mean 32 ±
29.6 months), 70% of responders had died.
HRQoL scores 3 months after the diagnostic process
SF-36
The highest mean scores were for the physical- and
social-functioning dimensions and for mental health
(50.1 ± 27.2, 55.5 ± 28 and 52.5 ± 21.6, respectively), and
the lowest score was for the physical role dimension
(17.9 ± 32.2) - Table 2.
QLQ C-30
For the functioning dimensions, the highest mean score
was for cognitive functioning (74.6 ± 25.9) and the lowest
was for role functioning (47.2 ± 34.1). For symptom di-
mensions, the lowest score was for diarrhoea (11.5 ± 24.2)
and the highest was for fatigue (59.7 ± 27.7) – Table 3.
There were few (from 1 to 5) missing data in both
questionnaires (see the N on Tables 2 and 3).
3 months after the diagnosis process
Status at May 1, 2010
429 patients received a diagnosis of 
non-small-cell lung cancer (NSCLC)
67 patients died
362 patients were eligible 
230 completed the SF-36
132 patients did not 
return the SF-36 
230 completed the QLQ C-30 
132 patients did not return 
the QLQ C-30
169 patients 
had died
61 were still 
alive
178 patients 
had died
52 were still 
alive
Figure 1 Patients with non-small-cell lung cancer (NSCLC) who participated in the quality-of-life study 3 months after the diagnostic
process. SF-36 =Medical Outcomes Survey Short form 36; QLQ C-30 = European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire Core-30.
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Prognostic value of HRQoL scores for patient survival
Bivariate analysis
Disease stage and treatments independently predicted sur-
vival (Table 4). Patients with stage III and those with stage
IV have much more than double risks of death (p < 0.001
to p = 0.02 respectively) compared to patients with stage I
or II. Patients treated by surgery alone or surgery with
chemo/radiotherapy before QoL measure was associated
with a lower risk of death (p < 0.001). On the SF-36,
scores ≥50 of bodily pain, emotional role, social func-
tioning and vitality (p = 0.001 to p = 0.03; Table 4), in-
dependently predicted a better survival. Score ≥50 on
general health was also related to a better survival (HR
0.625 [0.437 – 0.895], p = 0.01) – Table not shown. On
the questionnaire QLQ C-30, scores ≥50 of the function
domains except the cognitive- and emotional-functioning
were also related to a better survival (physical-, role- and
social-functioning; p = 0.009 to p = 0.005; Table 5); and
scores <50 of 4 of 8 symptoms’ (less fatigue, constipation,
nausea/vomiting, and appetite loss; p = 0.004 to p = 0.01),
independently predicted higher risk of death. Scores ≥50
on general QoL were also related to a better survival
(Table 5).
Survival analysis
The comparison of patients’ survival according to the
HRQoL scores showed that:
– On SF-36,
patients with Bodily pain (BP) scores <50, the
median survival was 9 months (CI 95%: 7 – 16)
compared to 35.5 (26 – 57) if scores were ≥ 50,
p < 0.001;
for Social functioning, those with score <50 had
a median of 8 months (5 – 25) vs 25.5 (15 – 37),
p = 0.01 in patients with score ≥50;
for Global health <50 the median survival was 14
(8–20) vs 37 (20 – 58) if scores ≥ 50.
Table 1 Characteristics of patients with non-small-cell
lung cancer (NSCLC) who completed the SF-36 and QLQ
C-30 health-related quality of life (HRQoL) surveys
SF-36 (n = 230) QLQ C-30 (n = 230)
Mean ± SD n [%] Mean ± SD n [%]
Age 60.2 ± 10.7 60.1 ± 10.7
Sex:
- Men 186 [80.9] 184 [80.0]
- Women 44 [19.1] 46 [20.0]
Stage of cancer
- I or II 49 [21.3] 48 [20.9]
- III 136 [59.1] 141 [61.3]
- IV 45 [19.6] 41 [17.8]
Treatments before the HRQoL measurement
- Chemotherapy only 133 [57.8) 132 [57.4]
- Radiotherapy only or with
chemotherapy
26 [11.3] 24 [10.4]
- Surgery alone or surgery and
(radiotherapy or chemotherapy)
71 [30.9] 74 [32.2]
Education level
- Primary 64 [28.7] 64 [29.6]
- Secondary 144 [64.6] 136 [63.0]
- Post-secondary 15 [6.7] 16 [7.4]
SF-36 =Medical Outcomes Survey Short Form 36; QLQ C-30 = European
Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core-30.
Treatments before HRQoL measurement were divided into 3 classes for all Cox
multivariate models:
1) Chemotherapy only.
2) Radiotherapy or chemotherapy or both.
3) Surgery alone or surgery and radiotherapy or chemotherapy.
Table 2 Description of SF-36 scores at 3 months of follow up
N Mean SD* Median Q1 Q3
Physical functioning 230 50.1 27.2 50 27.8 70
Physical role 229 17.9 32.2 0 0 25
Bodily pain 229 46.2 25 41 31 62
Mental health 228 52.5 21.6 52 36 68
Emotional functioning 226 24.6 38 0 0 33.3
Social functioning 230 55.5 28 50 37.5 75
Vitality 227 32.9 19.6 30 20 45
General health 230 39.5 19.3 37 25 52
PCS 225 34.8 8.4 34.7 28.2 40.9
MCS 225 37.2 11.3 35.7 28.9 45.1
*SD = Standard deviation.
Table 3 Description of QLQ C-30 scores at 3 months of
follow up
N Mean SD* Median Q1 Q3
Physical functioning 230 63.2 23.9 66.7 53.3 80
Role functioning 228 47.2 34.1 50 16.7 66.7
Cognitive functioning 230 74.6 25.9 83.3 66.7 100
Emotional functioning 230 58.6 28.2 66.7 33.3 83.3
Social functioning 229 55.5 33.7 66.7 33.3 83.3
Fatigue 230 59.7 27.7 55.6 33.3 77.8
Pain 230 43.5 33.5 33.3 16.7 66.7
Nausea and vomitting 230 20.6 29.1 0 0 33.3
Insomnia 229 44.3 37.2 33.3 0 66.7
Constipation 228 28.1 33.9 33.3 0 33.3
Dyspnea 230 55.5 34.5 66.7 33.3 100
Diarrhea 229 11.5 24.2 0 0 0
Appetit loss 229 40 38.3 33.3 0 66.7
Global QoL 230 45.6 20.2 50 33.3 58.3
*SD = Standard deviation.
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– On QLQ C-30, patients with the general QoL score
<50, had a median survival of 9 months (7 – 17)
compared to 29.5 (9 – 45) if scores ≥ 50.
Multivariate analysis
SF-36
1) For the model without general health scores,
higher bodily pain and social functioning scores
(≥50) was associated with a lower risk of death
(hazard ratio [HR] 0.589, 95% confidence interval
[0.400–0.840], p = 0.05 and HR = 0.652 [0.455-0.935],
p = 0.004).
2) For the model with the general health score alone,
higher score (≥50) on this domain was also
associated with lower risk of death (HR = 0.625
[0.437-0.895], p = 0.01).
QLQ C-30
1) For models without global HRQoL, no association
was observed between HRQoL dimensions and
patients’ survival.
2) For the model with global HRQoL only, higher
global HRQoL score (≥50) was associated with lower
risk of death (HR = 0.689 [0.501-0.946], p = 0.02)
(Table 5).
Table 4 The prognostic effect of SF-36 HRQoL dimensions 3 months after NSCLC diagnosis on survival (bivariate and
multivariate analyses)
Model without general health
Variables
Bivariate analysis Multivariate analysis
HR 95% CI P HR 95% CI p
HRQoL dimensions
Physical functioning ≥50 0.750 0.550 - 1.023 0.069 0.946 0.667 - 1.341 0.755
Physical role ≥50 0.651 0.428 - 0.991 0.046 0.576 0.326 - 1.016 0.057
Bodily pain ≥50 0.590 0.430 - 0.810 0.001 0.580 0.400 - 0.840 0.004
Emotional role ≥50 0.665 0.452 - 0.980 0.039 1.564 0.923 - 2.648 0.096
Social functioning ≥50 0.676 0.489 - 0.933 0.017 0.652 0.455 - 0.935 0.020
Mental health ≥50 0.792 0.581 - 1.081 0.142
Vitality ≥50 0.605 0.405 - 0.905 0.015 0.784 0.472 - 1.303 0.349
Patient characteristics
Age 1.002 0.9 - 1.02 0.798 1.102 1.041 - 1.167 <0.001
Sex:
- Men 1 1
- Women 0.859 0.575 - 1.285 0.460 0.556 0.351 - 0.881 0.012
Education level:
- Primary 1
- Secondary 0.820 0.581 - 1.157 0.259
- Post secondary 0.739 0.374 - 1.461 0.384
Stage of cancer
- Stage I - II 1 1
- Stage III 1.670 1.088 - 2.565 0.019 21.388 3.460 - 132.187 0.001
- Stage IV 3.341 2.025 - 5.511 <0.001 633.964 21.799 - 18437.11 <0.001
Treatment before the HRQoL measurement
- Chemotherapy only 1 1
- Chemo and radiotherapy 0.691 0.420 - 1.138 0.146 0.651 0.387 - 1.095 0.106
- Surgery alone or surgery and radiotherapy
or chemotherapy
0.219 0.144 - 0.333 <0.001 0.186 0.115 - 0.300 <0.001
Interaction
Age * Stage of cancer 0.969 0.945 - 0.994 0.016 0.952 0.926 - 0.978 <0.001
*The interaction between Age and Stage of cancer.
HR = hazard ratio; 95% CI = 95% confidence interval.
Scores range from 0 to 100, with high scores reflecting better QoL.
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Table 5 The prognostic effect of QLQ C-30 variables 3 months after NSCLC diagnosis on survival (bivariate and
multivariate analyses)
Model without global health
Bivariate analysis Multivariate analysis
Variables HR 95% CI p HR 95% CI p
Functioning domains (100 = good)
Physical functioning ≥50 0.612 0.431 - 0.869 0.006 0.787 0.506 - 1.226 0.289
Role functioning ≥50 0.640 0.469 - 0.874 0.005 0.907 0.573 - 1.437 0.677
Cognitive functioning ≥50 0.916 0.554 - 1.152 0.733
Social functioning ≥50 0.656 0.477 - 0.900 0.009 1.058 0.695 - 1.609 0.794
Emotional functioning ≥50 0.841 0.604 - 1.170 0.304
Symptom domains (100 = severe)
Pain <50 0.774 0.567 - 1.056 0.106
Fatigue <50 0.616 0.445 - 0.851 0.003 0.703 0.471 - 1.049 0.084
Sleep disturbance <50 0.876 0.641 - 1.197 0.406
Constipation <50 0.660 0.460 - 0.948 0.024 0.786 0.523 - 1.181 0.246
Nausea and vomiting <50 0.624 0.434 - 0.897 0.011 0.849 0.529 - 1.363 0.498
Apetite loss <50 0.628 0.457 - 0.863 0.004 0.890 0.599 - 1.324 0.567
Diarhoea <50 0.660 0.373 - 1.168 0.153
Dyspnea <50 1.095 0.803 - 1.491 0.567
Patient characteristics
Age 1.011 0.979 - 1.044 0.497 1.085 1.023 - 1.152 0.007
Sex:
- Men 1 1
- Women 0.732 0.293 - 1.831 0.505 0.633 0.411 - 0.976 0.038
Education level:
- Primary 1
- Secondary 0.783 0.554 - 1.107 0.167
- Post secondary 0.695 0.352 - 1.372 0.294
Stage of cancer
- Stage I - II 1 1
- Stage III 1.971 0.916 - 4.239 0.011 13.463 2.036 - 89.038 0.007
- Stage IV 4.898 1.518 - 15.801 <0.001 207.281 6.471 - 6639.251 0.003
Treatment before the HRQoL measurement
- Chemotherapy only 1 1
- Chemo and radiotherapy 0.656 0.388 - 1.109 0.115 0.635 0.366 - 1.103 0.107
- Surgery alone or surgery and radiotherapy
or chemotherapy
0.229 0.152 - 0.345 <0.001 0.227 0.143 - 0.363 <0.001
Interaction
Age*stage of cancer 0.973 0.947 - 1.000 0.049 0.959 0.932 - 0.987 0.004
Model with global health only
Bivariate analysis Multivariate analysis
Variables HR 95% CI p HR 95% CI p
(100 = good)
Global HRQoL ≥50 0.688 0.504 - 0.938 0.018 0.689 0.501 - 0.946 0.021
Patient characteristics
Age 1.011 0.979 - 1.044 0.497 1.083 1.022 - 1.147 0.007
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For all models, among socio-demographic or clinical
characteristics: older age, stage III and IV were related
to higher risk of death. Surgery and radio/chemotherapy
as treatment was related to a decreased risk of death.
Older patients with stage 4 had a lower risk of death
than younger patients with the same stage of cancer (age by
stage interaction HR= 0.9 [0.9 – 0.9]; p < 0.001) (Tables 4,
and 5).
Discussion
This study showed that certain domains on health re-
lated quality of life, measured after the initial treatment,
were related to the survival of patients with non-small-
cell lung cancer. On the bivariate analysis, we observed
that better physical- and emotional-role, social function-
ing and vitality as well as lesser pain symptom on SF-36
(score ≥50) were related to a better patients’ survival. On
multivariate analysis, a persistent relation was observed
for 2 domains: lesser (high scores) Bodily pain and better
Social-functioning. The QLQ C-30 showed that on the
bivariate analysis, better (high scores) physical-, role-
and social functioning, and also global HRQoL as well
as lesser symptoms (low scores) on fatigue, constipa-
tion, nausea-vomiting and appetite loss were related to
a better survival. On the multivariate analysis, only a
better Global QoL found to be related to a better pa-
tient’s survival. This relation was observed independ-
ently of known prognostic variables i.e. age, sex, stage
of cancer, and initial treatments. Patients seemed to
live few months longer with better perceived health.
This multicenter, prospective study involved patients
with a wide variety of NSCLC severity (stage I to IV)
while they were undergoing treatments. With a follow-
up of 4 to 6 years, we could observe patient’s survival
and whether HRQoL during treatments period contin-
ued to be related to survival. It is well known that both
questionnaires that were used, the SF-36 and QLQ-C30,
had robust psychometric properties. Also that HRQoL is
one of measurements that revealed patients’ point of
view regarding his/her health status and encompass the
incidence and the extent of limitations due to physical
capacity, which might occur because of the disease itself or
the effects of treatment. Indeed, as stated by Franceshini
et al., 54% of patients with lung cancer report dyspnoea,
which contributes to the worsening of QoL, because this
symptom might limit the ability to perform activities of
daily living and to work [30].
Studies have shown different results on the relation
between sex and survival of patients with NSCLC. The
present study confirmed findings that women had a bet-
ter survival [31-34].
Readers need to be cautious in translating the results
of this study to other populations. First, we measured
HRQoL 3 months after the diagnostic process, so it rep-
resented patients’ perceptions of the overall early man-
agement of lung cancer, from diagnosis to therapy.
Table 5 The prognostic effect of QLQ C-30 variables 3 months after NSCLC diagnosis on survival (bivariate and
multivariate analyses) (Continued)
Sex:
- Men 1 1
- Women 0.732 0.293 - 1.831 0.505 0.682 0.452 - 1.029 0.068
Education level:
- Primary 1
- Secondary 0.783 0.554 - 1.107 0.167
- Post secondary 0.695 0.352 - 1.372 0.294
Stage of cancer
- Stage I - II 1 1
- Stage III 1.971 0.916 - 4.239 0.011 11.982 1.881 - 76.310 0.009
- Stage IV 4.898 1.518 - 15.801 <0.001 167.961 5.666 - 4979.331 0.003
Treatment before the HRQoL measurement
- Chemotherapy only 1 1
- Chemo and radiotherapy 0.656 0.388 - 1.109 0.115 0.690 0.406 - 1.173 0.171
- Surgery alone or surgery and radiotherapy
or chemotherapy
0.229 0.152 - 0.345 <0.001 0.239 0.151 - 0.377 <0.001
Interaction
Age*stage of cancer 0.973 0.947 - 1.000 0.049 0.962 0.935 - 0.989 0.007
*The interaction between Age and Stage of cancer.
HR = hazard ratio; 95% CI = 95% confidence interval.
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However, this time period may introduce some selection
bias because some patients had died or were lost to
follow-up before HRQoL measurement. Patients who
did not make it until a 3 month follow-up were older
and mostly had a stage 4 of cancer. Among potentials re-
sponders, more than half (63.5%) returned back completed
questionnaires, with few (from 1 to 5) missing data. Also,
there was neither socio-demographical nor clinical character-
istics difference between responders vs non responders. Sec-
ond, previous studies showed poor performance status
associated with worse survival and good performance with
better survival [15,16,35]. We had information on treatments
that were performed after the HRQoL measurement and we
assumed, according to standards, that these treatments were
prescribed in accordance with each patient’s condition, inte-
grating performance status. Also, we did not dispose of infor-
mation regarding the stage of treatment and therefore could
not confirm the hypothesis that this variable may relate to
survival.
Previous studies showed that better HRQoL scores
measured at baseline (before any treatment) related to
better survival of patients with cancer [15,16,36,37]. This
study confirmed previous ones that reported that better
global QoL (QLQ C-30) as the strongest predictor of
better survival [15,36,37]. However it did not find per-
ceived pain as an independent predictor, as showed by
another study for patients with stage III or IV NSCLC
measured at diagnosis [16]. In the present study, we
measured HRQoL 3 months after the diagnosis, when
cancer management and treatments were ongoing. The
mean scores on the SF-36 were increased by +0.5 to +6
points for patients who had some surgical treatment
(n = 74) before HRQoL measurement than for those
who did not. The results of our study suggested that,
in addition to previous studies showing baseline HRQoL
affecting survival, perceived lesser-pain and better social
functioning measured by the SF-36 and perceived general
QoL on QLQ C-30 at 3 months after the diagnosis may
still affect survival. The better the HRQoL scores, the bet-
ter the survival probability. As suggested by Gotay et.al.,
changes in HRQOL may be an early warning system that
can be useful for clinical decision making, because HRQOL
may deteriorate before disease progression is evident by
other measures [36]. Although the observed impact of
HRQoL may not be that strong, it plays a very important
role besides other factors known that can influence these
patients’ survival. However, further studies are needed to
explore the fluctuation over time of HRQoL and whether
this fluctuation, if it exists and depending on its time of
measurement, is related to patient survival.
Conclusion
Measured after the initial treatment, this study showed a
persistent relation between HRQoL and survival of patients
with non-small lung cancer. Lesser perceived pain, a better
perception on general health and general QoL are found to
be related to a better chance to survive few months longer.
This relation was observed independently of known prog-
nostic variables i.e. age, sex, stage and initial treatments.
Our results have implications for clinical practice. Clini-
cians may integrate these measures in their battery of indi-
cators to continue monitoring patient health after the
beginning of treatment and to carefully examine symptoms
in self-rated HRQoL assessment in order to improve pa-
tients’ survival. If used in routine practice, it may also be
useful to facilitate communication among clinicians, health
professionals and patients to identify the most adaptable
cancer management.
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